Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:LFCR) with a Buy and raises the price target from $8 to $10.
Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:LFCR) with a Buy and raises the price target from $8 to $10.